Monday, November 15, 2021 8:39:03 AM
@impactstemcell
We're thrilled to be working with @humanigen to deliver this trial of #lenzilumab for treating high-risk acute graft versus host disease following allogeneic stem cell transplantation, led by Professor Adrian Bloor of @TheChristieNHS #GvHD #ASCT @AnthonyNolan @NHSBT @LeukUK https://t.co/2R9sbNP7gK
— ASCENT - Accelerated Stem CEll traNsplant Trials (@crctuASCENTteam) November 15, 2021
We're thrilled to be working with @humanigen to deliver this trial of #lenzilumab for treating high-risk acute graft versus host disease following allogeneic stem cell transplantation, led by Professor Adrian Bloor of @TheChristieNHS
#GvHD #ASCT @AnthonyNolan @NHSBT @LeukUK
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM